Bonaventura Clotet

Summary

Affiliation: Hospital Universitari Germans Trias i Pujol
Country: Spain

Publications

  1. ncbi request reprint Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
    Bonaventura Clotet
    IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, UAB, Universitat de Vic, Catalonia, Spain Electronic address
    Lancet 383:2222-31. 2014
  2. pmc Changes in codon-pair bias of human immunodeficiency virus type 1 have profound effects on virus replication in cell culture
    Gloria Martrus
    Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona UAB, Badalona 08916, Spain
    Retrovirology 10:78. 2013
  3. pmc Limited cross-border infections in patients newly diagnosed with HIV in Europe
    Dineke Frentz
    Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands
    Retrovirology 10:36. 2013
  4. pmc The infectious synapse formed between mature dendritic cells and CD4(+) T cells is independent of the presence of the HIV-1 envelope glycoprotein
    Maria T Rodriguez-Plata
    AIDS Research Institute IrsiCaixa, Institut d Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, 08916, Spain
    Retrovirology 10:42. 2013
  5. pmc HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
    Ana B Abecasis
    Unidade de Saúde Pública Internacional e Bioestatística, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal
    Retrovirology 10:7. 2013
  6. pmc Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients
    Kristof Theys
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    Retrovirology 9:81. 2012
  7. pmc Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome
    Marta Curriu
    Institut de Recerca de la SIDA, IrsiCaixa HIVACAT, Institut d Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain
    J Transl Med 11:68. 2013
  8. pmc Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions
    Anuska Llano
    IrsiCaixa AIDS Research Institute HIVACAT, Hospital Universitari Germans Trias y Pujol, Badalona, Spain
    J Transl Med 11:48. 2013
  9. pmc Definition of the viral targets of protective HIV-1-specific T cell responses
    Beatriz Mothe
    IrsiCaixa AIDS Research Institute HIVACAT, Badalona, Spain
    J Transl Med 9:208. 2011
  10. pmc On the steps of cell-to-cell HIV transmission between CD4 T cells
    Isabel Puigdomènech
    Fundació irsiCaixa HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Germans Trias, Universitat Autonoma de Barcelona, Badalona 08916, Barcelona, Catalonia, Spain
    Retrovirology 6:89. 2009

Detail Information

Publications156 found, 100 shown here

  1. ncbi request reprint Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
    Bonaventura Clotet
    IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, UAB, Universitat de Vic, Catalonia, Spain Electronic address
    Lancet 383:2222-31. 2014
    ..In FLAMINGO, we compared dolutegravir with darunavir plus ritonavir in individuals naive for antiretroviral therapy...
  2. pmc Changes in codon-pair bias of human immunodeficiency virus type 1 have profound effects on virus replication in cell culture
    Gloria Martrus
    Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona UAB, Badalona 08916, Spain
    Retrovirology 10:78. 2013
    ..Here, we applied the previously described synthetic attenuated virus engineering (SAVE) approach to HIV-1...
  3. pmc Limited cross-border infections in patients newly diagnosed with HIV in Europe
    Dineke Frentz
    Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands
    Retrovirology 10:36. 2013
    ..In this study, phylogenetic associations among HIV of newly diagnosed patients were determined across Europe...
  4. pmc The infectious synapse formed between mature dendritic cells and CD4(+) T cells is independent of the presence of the HIV-1 envelope glycoprotein
    Maria T Rodriguez-Plata
    AIDS Research Institute IrsiCaixa, Institut d Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, 08916, Spain
    Retrovirology 10:42. 2013
    ....
  5. pmc HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
    Ana B Abecasis
    Unidade de Saúde Pública Internacional e Bioestatística, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal
    Retrovirology 10:7. 2013
    ..Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes...
  6. pmc Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients
    Kristof Theys
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    Retrovirology 9:81. 2012
    ....
  7. pmc Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome
    Marta Curriu
    Institut de Recerca de la SIDA, IrsiCaixa HIVACAT, Institut d Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain
    J Transl Med 11:68. 2013
    ..Although several immunological abnormalities have been described in CFS, their heterogeneity has limited diagnostic applicability...
  8. pmc Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions
    Anuska Llano
    IrsiCaixa AIDS Research Institute HIVACAT, Hospital Universitari Germans Trias y Pujol, Badalona, Spain
    J Transl Med 11:48. 2013
    ..As re-exposure to viral antigens may also boost the production of (neutralizing) antibodies, we also assessed the neutralizing activities during STI cycles...
  9. pmc Definition of the viral targets of protective HIV-1-specific T cell responses
    Beatriz Mothe
    IrsiCaixa AIDS Research Institute HIVACAT, Badalona, Spain
    J Transl Med 9:208. 2011
    ..However, current HIV vaccine designs are largely based on viral sequence alignments only, not incorporating experimental data on T cell function and specificity...
  10. pmc On the steps of cell-to-cell HIV transmission between CD4 T cells
    Isabel Puigdomènech
    Fundació irsiCaixa HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Germans Trias, Universitat Autonoma de Barcelona, Badalona 08916, Barcelona, Catalonia, Spain
    Retrovirology 6:89. 2009
    ..Chronologically, HIV transfer is an early event occurring immediately after the VS formation, which precedes but does not inevitably lead to transmission, a late event resulting in infection...
  11. ncbi request reprint Once-daily dosing of nevirapine in HAART
    Bonaventura Clotet
    Hospital Universitari Germans Trias I Pujol and irsiCaixa Foundation, Ctra de Canyet s n 08916, Barcelona, Catalonia, Spain
    J Antimicrob Chemother 61:13-6. 2008
    ..The NODy study will evaluate the efficacy and safety of switching to nevirapine once daily compared with remaining on twice-daily treatment...
  12. ncbi request reprint Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
    Bonaventura Clotet
    Hospital Universitari Germans Trias I Pujol and irsiCaixa Foundation, Ctra de Canyet s n 08916, Barcelona, Catalonia, Spain
    Lancet 369:1169-78. 2007
    ..We did a pooled subgroup analysis to update results at week 48 for patients receiving the recommended dose of darunavir-ritonavir compared with those receiving other protease inhibitors (PIs)...
  13. doi request reprint Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials
    Bonaventura Clotet
    Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    J Antimicrob Chemother 65:2450-4. 2010
    ..DUET-1 and DUET-2 are registered with clinicaltrials.gov (NCT00254046 and NCT00255099, respectively)...
  14. doi request reprint Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions
    Laila Darwich
    IrsiCaixa Foundation, Center for Epidemiological Studies on Sexually Transmitted Infections and AIDS in Catalonia, Barcelona, Spain
    AIDS Res Hum Retroviruses 24:725-32. 2008
    ..A genotypic profile could provide clinicians with a predictive tool for time off therapy when TI is required in patients with suppressed viremia in whom nadir CD4(+) count is not available...
  15. ncbi request reprint Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Germans Trias i Pujol Hospital, Badalona, Spain
    Antivir Ther 11:47-51. 2006
    ..To assess if enfuvirtide (ENF) increases antiviral activity of a highly active four-drug antiretroviral (ARV) regimen containing lopinavir/ritonavir, efavirenz, lamivudine and tenofovir in ARV-naive, HIV-infected patients...
  16. doi request reprint The magnitude of interferon-gamma responses to human cytomegalovirus is predictive for HIV-1 disease progression
    Laila Darwich
    Fundació IrsiCaixa HIVACAT Fundació, Hospital Germans Trias i Pujol, Badalona, Spain
    J Acquir Immune Defic Syndr 49:507-12. 2008
    ..We have investigated whether the magnitude of the overall peripheral blood mononuclear cell responses to HCMV stimulation correlated with HIV-1 progression...
  17. ncbi request reprint Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir
    Francesc Cunyat
    Fundacio irsiCaixa, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, Hospital Germans Trias, Universitat Autonoma de Barcelona, Badalona, Barcelona, Catalonia, Spain
    Antivir Ther 15:431-6. 2010
    ..The pathways of resistance to atazanavir (ATV) and amprenavir (APV) converge at position 50 of HIV protease. The determinants of cross-resistance were analysed during in vitro sequential or concomitant combination pressure with both drugs...
  18. doi request reprint Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients
    Jose Molto
    Lluita contra Sida Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 15:219-25. 2010
    ..We explored a treatment simplification strategy to darunavir/ritonavir 900/100 mg once daily guided by the darunavir virtual inhibitory quotient (vIQ) in patients receiving salvage therapy with darunavir/ritonavir 600/100 mg twice daily...
  19. ncbi request reprint Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption
    Laila Darwich
    IrsiCaixa Foundation, Badalona, Spain
    Antivir Ther 13:945-51. 2008
    ..We evaluated the selection of NNRTI-related mutations and the coefficient of variation of NNRTI plasma concentrations during different TI periods...
  20. doi request reprint Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:713-7. 2011
    ....
  21. ncbi request reprint Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both
    Angel Luis Ballesteros
    HIV Clinical Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 9:969-77. 2004
    ....
  22. ncbi request reprint Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Spain
    Antivir Ther 9:335-42. 2004
    ..To assess the efficacy and safety of a once-daily antiretroviral regimen in HAART-experienced subjects with long-lasting viral suppression...
  23. ncbi request reprint Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients
    Lidia Ruiz
    Fundació IrsiCaixa and HIV Clinical Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    AIDS 21:169-78. 2007
    ..We evaluated the safety of CD4 cell count and plasma HIV-1 RNA (pVL)-guided treatment interruptions (GTI) and determined predictors of duration of treatment interruption...
  24. ncbi request reprint Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice
    José Ramón Santos
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:129-34. 2009
    ....
  25. ncbi request reprint Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment
    Marta Massanella
    Fundació irsiCaixa HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, Hospital Germans Trias, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain
    Antivir Ther 15:333-42. 2010
    ..We evaluated the effect of different doses of pegylated interferon (PEG-IFN)-alpha2a/ribavirin (RBV) on several T-cell activation markers in HIV-HCV-coinfected patients and their relationship with changes in plasma HCV RNA...
  26. pmc Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects
    Francisco M Codoñer
    Institut de Recerca de la SIDA irsiCaixa HIVACAT, Badalona, Spain
    PLoS ONE 6:e19461. 2011
    ..To explore the potential of deep HIV-1 sequencing for adding clinically relevant information relative to viral population sequencing in heavily pre-treated HIV-1-infected subjects...
  27. ncbi request reprint The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy
    Eugenia Negredo
    Lluita contra la SIDA, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    AIDS 20:619-21. 2006
    ..Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4...
  28. doi request reprint Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Barcelona, Spain
    Clin Infect Dis 49:892-900. 2009
    ..This study aimed to evaluate in vivo the effects of NRTI withdrawal on mitochondrial parameters and body fat distribution...
  29. doi request reprint High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study
    Anna Bonjoch
    Lluita contra la SIDA Foundation, University Hospital Germans Trias, Barcelona, Spain
    AIDS 24:2827-33. 2010
    ..Low bone mineral density (BMD) is an emerging metabolic condition in HIV-infected patients; however, data on progression of this disease are scarce...
  30. pmc Trans-infection but not infection from within endosomal compartments after cell-to-cell HIV-1 transfer to CD4+ T cells
    Marc Permanyer
    IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Spain
    J Biol Chem 287:32017-26. 2012
    ..Our results suggest that endocytosis is not a mechanism of infection of primary CD4 T cells, but may serve as a reservoir capable of inducing trans-infection of cells after the release of HIV particles to the extracellular environment...
  31. ncbi request reprint Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen
    Cecilia Cabrera
    IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS 20:2075-80. 2006
    ..To analyse the genetic changes in the gp41 protein in HIV-infected patients with detectable plasma viraemia receiving a long-term salvage enfuvirtide regimen...
  32. doi request reprint Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS Res Hum Retroviruses 26:1191-6. 2010
    ....
  33. ncbi request reprint Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy
    Maria José Buzón
    IrsiCaixa Foundation, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 13:881-93. 2008
    ..We aimed to elucidate whether long-term highly active antiretroviral therapy (HAART) targeting PR and RT could influence raltegravir susceptibility and the fitness of IN...
  34. ncbi request reprint Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide
    Anna Bonjoch
    Lluita contra la SIDA Foundation, AIDS Care Unit, Hospital Universitari Germans Trias i Pujol, Universitat Auntònoma de Barcelona, Badalona, Spain
    AIDS 20:1896-8. 2006
    ..5%) and in no patients, respectively, (P = 0.007). The CD4 cell decrease in failure patients was 5% (P = ns). These results suggest that enfuvirtide should be maintained until new active drugs became available...
  35. ncbi request reprint Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response
    Daniel Fuster
    HIV Clinical Unit Fundació de Lluita contra la SIDA Internal Medicine Service University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    Antivir Ther 11:473-82. 2006
    ..To assess the efficacy and safety of an extended treatment period in HIV/hepatitis C virus (HCV)-coinfected patients without early virological response (EVR)...
  36. ncbi request reprint HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro
    Gemma Moncunill
    Retrovirology Laboratory IrsiCaixa and AIDS Unit, Hospital Germans Trias i Pujol, Badalona, Spain
    AIDS 22:23-31. 2008
    ..Selection of resistant HIV-1 to CCR5 agents in cell culture has often occurred in the absence of coreceptor switch. With CCR5 antagonists currently in clinical trials, their impact on coreceptor use is still in doubt...
  37. ncbi request reprint Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Ther Drug Monit 29:648-51. 2007
    ..Therapeutic drug monitoring may be useful in this setting...
  38. doi request reprint Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:432-8. 2009
    ..To assess the Efficacy and safety of switching from HAART containing enfuvirtide to raltegravir as a simplification strategy in patients with viral suppression and intolerance to enfuvirtide...
  39. doi request reprint Prevalence, clearance, and incidence of human papillomavirus type-specific infection at the anal and penile site of HIV-infected men
    Laila Darwich
    Lluita contra la SIDA Foundation, Badalona, Spain
    Sex Transm Dis 40:611-8. 2013
    ..We studied the type-specific infection of human papillomavirus (HPV) at the anal canal and penile site in a cohort of HIV-infected men...
  40. ncbi request reprint Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens
    Eugenia Negredo
    Germans Trias i Pujol University Hospital, Lluita contra la SIDA and IrsiCaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
    Antivir Ther 13:231-40. 2008
    ..We assessed whether a simple reduction of the ddl dose in patients receiving ddl (400 mg/day) and TDF could revert this side effect...
  41. ncbi request reprint Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3
    Guillem Sirera
    HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona U A B, Badalona, Barcelona, Spain
    J Antimicrob Chemother 61:191-4. 2008
    ....
  42. doi request reprint Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Ther Drug Monit 32:93-6. 2010
    ..Atazanavir Ctroughs were compared between Days 0 and 28. Atazanavir and nevirapine Ctroughs at Day 28 were compared with historical controls receiving either 400 mg atazanavir once daily or 200 mg nevirapine twice daily...
  43. ncbi request reprint Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
    Jose A Muñoz-Moreno
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain
    J Neurovirol 16:208-18. 2010
    ..Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning...
  44. ncbi request reprint Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study
    Lidia Ruiz
    Retrovirology Laboratory, IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Infect Dis 188:977-85. 2003
    ..66; 95% confidence interval, 0.47-0.93; P=.021). A prior STI seems to confer no additional benefit to subsequent virological or immunological outcomes of a salvage regimen...
  45. pmc HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4
    Isabel Puigdomènech
    Fundacio irsiCaixa, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona 08916, Barcelona, Catalonia, Spain
    Retrovirology 5:32. 2008
    ..Here, we evaluate their role in viral transmission between different HIV producing cells and primary CD4 T cells...
  46. doi request reprint Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
    Josep Mallolas
    Hospital Clinic Universitari IDIBAPS, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 51:29-36. 2009
    ..To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r...
  47. doi request reprint Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial
    Anna Bonjoch
    HIV Unit and Fundació Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Barcelona, Catalonia, Spain
    J Antimicrob Chemother 68:1382-7. 2013
    ..To evaluate the safety and efficacy of switching the third drug of antiretroviral treatment to maraviroc in aviraemic subjects infected with R5 HIV...
  48. ncbi request reprint Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis
    Jose Molto
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Clin Pharmacokinet 46:85-92. 2007
    ..To assess the influence of hepatitis C virus (HCV) co-infection and the extent of liver fibrosis on lopinavir/ritonavir pharmacokinetics in HIV-infected patients without liver function impairment...
  49. doi request reprint Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery
    Marta Massanella
    AIDS Research Institute, IrsiCaixa HIVACAT, Institut d Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Catalonia, Spain
    AIDS 26:2285-93. 2012
    ..Immunodiscordance is characterized by partial CD4 T-cell immunodeficiency and increased inflammation, activation and immunosenescence in both CD4 and CD8 T cells...
  50. doi request reprint Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    J Antimicrob Chemother 67:1462-9. 2012
    ..To assess the most frequent resistance-associated mutations (RAMs) to lopinavir/ritonavir in a cohort of patients attended in daily practice...
  51. pmc The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype
    Francesc Cunyat
    IrsiCaixa HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Germans Trias, Universitat Autonoma de Barcelona, Catalonia, Spain
    Retrovirology 9:15. 2012
    ....
  52. ncbi request reprint Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Clin Pharmacokinet 47:681-92. 2008
    ..It is coformulated with low doses of ritonavir in order to enhance its pharmacokinetic profile. After oral administration, plasma concentrations of lopinavir can vary widely between different HIV-infected patients...
  53. pmc Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Ctra de Canyet, Badalona, Barcelona, Spain
    Antimicrob Agents Chemother 52:3928-32. 2008
    ..We suggest targeting a darunavir vIQ of 1.5 for achieving long-term viral suppression...
  54. ncbi request reprint Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies
    Bonaventura Clotet
    Fundaciò IrsiCaixa Laboratori de Retrovirologia, and HIV Unit Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 45:479-81. 2007
  55. ncbi request reprint Mild improvement in mitochondrial function after a 3-year antiretroviral treatment interruption despite persistent impairment of mitochondrial DNA content
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Curr HIV Res 8:379-85. 2010
    ..The ability of a prolonged antiretroviral treatment interruption to reverse mitochondrial toxicity was evaluated in a sub-study of TIBET, a prospective trial examining antiretroviral treatment interruption guided by CD4+ cell count...
  56. ncbi request reprint Immunological and virological study of enfuvirtide-treated HIV-positive patients
    Jordi Barretina
    Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Spain
    AIDS 18:1673-82. 2004
    ..To evaluate the predictive value and evolution of immunological and virological parameters related to HIV entry and pathogenesis in patients receiving enfuvirtide (ENF) plus an optimized regimen...
  57. ncbi request reprint R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism
    Julia Blanco
    Retrovirology Laboratory, Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Catalonia, Spain
    J Leukoc Biol 76:804-11. 2004
    ..Env tropism and coreceptor expression but not differential killing mechanisms seem to govern the extent of cytopathic effects induced by HIV infection...
  58. doi request reprint Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification
    Marta Massanella
    IrsiCaixa, Institut de Recerca de la SIDA, Institut d Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    J Acquir Immune Defic Syndr 63:152-60. 2013
    ..However, HAART intensification exclusively reduced CD8 T-cell activation...
  59. doi request reprint Distribution of human papillomavirus genotypes in anal cytological and histological specimens from HIV-infected men who have sex with men and men who have sex with women
    Laila Darwich
    Lluita contra la SIDA Foundation, Badalona, Spain
    Dis Colon Rectum 56:1043-52. 2013
    ..However, most studies have focused only on men who have sex with men (MSM)...
  60. ncbi request reprint Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain
    Clin Infect Dis 41:901-5. 2005
    ..Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period...
  61. ncbi request reprint Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, and Universidad Autonoma de Barcelona, Spain
    J Antimicrob Chemother 60:436-9. 2007
    ..The objective of this study was to assess the effectiveness and safety of monotherapy with lopinavir/ritonavir as a treatment simplification strategy in HIV-infected patients with viral suppression outside a clinical trial setting...
  62. doi request reprint A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors
    Maria José Buzón
    Institut de Recerca de SIDA IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    J Antimicrob Chemother 67:32-8. 2012
    ..We describe the molecular mechanism of a non-infectious HIV-1 protease phenotypic assay in eukaryotic cells and validate its applicability as a tool for monitoring drug resistance...
  63. doi request reprint Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain
    J Antimicrob Chemother 68:2358-62. 2013
    ..Immune hyperactivation in immunodiscordant patients can induce residual HIV replication and limit CD4 T cell recovery. We assessed the impact of raltegravir intensification on CD4 T cell recovery and viral persistence...
  64. ncbi request reprint Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells
    Gerard Minuesa
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, 08190 Badalona, Barcelona, Spain
    J Pharmacol Exp Ther 324:558-67. 2008
    ..The identification of the transporter involved in each specific drug uptake in immune cells could help to optimize pharmacological therapeutic responses...
  65. ncbi request reprint Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Barcelona, Spain
    J Antimicrob Chemother 61:400-4. 2008
    ..Cellular cholesterol is essential for HIV replication and may control HIV spread. HIV, in turn, appears to control cholesterol metabolism...
  66. ncbi request reprint Longitudinal study on mitochondrial effects of didanosine-tenofovir combination
    Sonia Lopez
    Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 22:33-9. 2006
    ..The particular relevance of either ddI, TDF, or any interaction between them in such a mitochondrial dysfunction remains to be established...
  67. pmc Time of progression to osteopenia/osteoporosis in chronically HIV-infected patients: screening DXA scan
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    PLoS ONE 7:e46031. 2012
    ..Our objective was to assess how often a dual-energy x-ray absorptiometry (DXA) scan should be performed by assessing time of progression to osteopenia/osteoporosis...
  68. ncbi request reprint Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses
    Guerau Fernandez
    Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona UAB, Badalona, Spain
    J Gen Virol 87:1285-94. 2006
    ..In contrast, R5 variants from R5 phenotype samples were highly heterogeneous and subject to positive selective pressures...
  69. pmc Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
    Br J Clin Pharmacol 63:715-21. 2007
    ....
  70. doi request reprint Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications
    Eugenia Negredo
    Lluita contra Sida Foundation, Institut de Recerca en Ciències de Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Infect Dis 50:1300-8. 2010
    ..Although antiretroviral therapy improves immune response, some human immunodeficiency virus-infected patients present unsatisfactory CD4 T cell recovery despite achieving viral suppression, resulting in increased morbidity and mortality...
  71. doi request reprint Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages
    Ester Ballana
    Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    Blood 113:1278-86. 2009
    ..In conclusion, our results reveal a significant role of integrin alphaV-mediated adhesion in HIV-1 infection of macrophages...
  72. doi request reprint Low levels of adherence to antiretroviral therapy in HIV-1-infected women with menstrual disorders
    Carmina R Fumaz
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain
    AIDS Patient Care STDS 23:463-8. 2009
    ..The subjective attribution of these irregularities to antiretrovirals seems to affect medication intake, possibly favoring negative clinical consequences...
  73. ncbi request reprint Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins
    Eugenia Negredo
    Lluita contra la SIDA, Germans Trias i Pujol Hospital, Universitat Autonoma de Barcelona, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
    AIDS 20:2159-64. 2006
    ..To assess the efficacy, safety, and pharmacokinetic interactions of ezetimibe in HIV-infected patients with poorly controlled antiretroviral-associated dyslipidaemia while taking pravastatin alone...
  74. ncbi request reprint Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients
    Cristina Tural
    HIV Clinical Unit, Internal Medicine Department, Fundació de la Lluita contra la SIDA, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 13:1047-55. 2008
    ..Suboptimal doses of ribavirin have been suggested to explain the diminished efficacy of pegylated interferon (PEG-IFN) plus ribavirin in hepatitis C virus (HCV)-HIV-coinfected patients...
  75. ncbi request reprint The anti-HIV activity of ADS-J1 targets the HIV-1 gp120
    Mercedes Armand-Ugon
    Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Barcelona, Spain
    Virology 343:141-9. 2005
    ..We conclude that ADS-J1 may bind to the HIV coreceptor binding site as its mechanism of anti-HIV activity...
  76. ncbi request reprint Reduced fitness of HIV-1 resistant to CXCR4 antagonists
    Mercedes Armand-Ugon
    Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Spain
    Antivir Ther 8:1-8. 2003
    ..Thus, viral resistance development to a CXCR4 antagonist such as AMD3100 is associated with reduced viral fitness...
  77. pmc Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    PLoS ONE 7:e37442. 2012
    ....
  78. doi request reprint Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine
    Vicens Diaz-Brito
    Hospital Clinic, University of Barcelona, Barcelona, Spain
    Antivir Ther 17:337-46. 2012
    ..A clinical trial comparing the rate of discontinuation and tolerability of two post-exposure prophylaxis (PEP) regimens was performed...
  79. doi request reprint Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells
    Marta Massanella
    Fundació irsiCaixa HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Barcelona, Catalonia, Spain
    AIDS 23:183-8. 2009
    ..We have evaluated the impact of antibodies against HIV envelope glycoproteins (gp120 and gp41) on cell-to-cell HIV transmission...
  80. ncbi request reprint Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death
    Jordi Barretina
    Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Spain
    Antivir Ther 8:155-61. 2003
    ..Protection of cells prior to infection from HIV envelope-dependent bystander effect could lead to a better immune restoration of HIV-1-infected patients that are treated with T-20...
  81. ncbi request reprint Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects
    Jose Molto
    HIV Clinical Unit Lluita Contra Ia Sida Foundation, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 20:1283-8. 2004
    ..Previous STIs do not influence time off therapy when HAART is definitively discontinued in chronically HIV-infected subjects. CD4 nadir is an important factor in the treatment discontinuation decision...
  82. pmc Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients
    Ester Aparicio
    Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain
    J Virol 85:5961-9. 2011
    ..Greater NS3/4A nucleotide heterogeneity and higher Shannon entropy values in nonresponders suggest that less HCV quasispecies complexity may favor a better response to pegIFN-RBV...
  83. doi request reprint Saquinavir exposure in HIV-infected patients with chronic viral hepatitis
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Antimicrob Chemother 63:992-7. 2009
    ....
  84. pmc Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein
    Berta Bosch
    Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    Antimicrob Agents Chemother 49:4296-304. 2005
    ....
  85. ncbi request reprint Naive CD4(+) T cells and recent thymic emigrant levels in treated individuals with HIV: clinical relevance
    Margarita Bofill
    Institució Catalana de Recerca i Estudis Avangats, HIV Unit, Hospital Universitari Germans Trias i Pujol, Ctra Canyet s n 08916 Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 22:893-6. 2006
    ..However, the probability of restarting therapy in these two groups of patients was independent of the levels of naive T cells, RTEs, or TRECs...
  86. doi request reprint A clathrin-dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell-T cell transmission
    Berta Bosch
    Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    Antiviral Res 80:185-93. 2008
    ....
  87. pmc In-depth characterization of viral isolates from plasma and cells compared with plasma circulating quasispecies in early HIV-1 infection
    Judith Dalmau
    AIDS Research Institute IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    PLoS ONE 7:e32714. 2012
    ....
  88. ncbi request reprint Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens
    Carmina R Fumaz
    HIV Unit, Fundació Lluita SIDA and IrsiCaixa Retrovirology Laboratory, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 29:244-53. 2002
    ....
  89. ncbi request reprint Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study
    Eugenia Negredo
    Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    Antivir Ther 9:889-93. 2004
    ..Alternation of antiretroviral drug regimens has been proposed as a novel treatment strategy for HIV infection. However, some concerns persist regarding antiviral efficacy, adherence, toxicity and resistance evolution in the long term...
  90. ncbi request reprint Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy
    Daniel Fuster
    HIV Clinical Unit Department, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona UAB, 08916 Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 20:1293-7. 2004
    ..HIV infection is associated with advanced liver fibrosis. HIV/HCV-coinfected individuals on HAART are at risk of developing end-stage liver disease despite virological success and immunological reconstitution...
  91. ncbi request reprint Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients
    Josep M Llibre
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    J Antimicrob Chemother 61:206-9. 2008
    ..To determine the feasibility and outcomes of long-distance interactive expert advice for treatment-experienced patients...
  92. pmc Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs
    Julia Blanco
    Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Catalonia, Spain
    Antimicrob Agents Chemother 49:3926-9. 2005
    ..In this assay, different anti-HIV envelope drugs showed characteristic inhibitory profiles for each measured parameter, allowing for the rapid identification of the mode of action of active compounds...
  93. doi request reprint ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression
    Ester Ballana
    Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    Clin Infect Dis 50:1022-32. 2010
    ..Genes and polymorphisms identified by large-scale analysis need to be followed up by means of functional assays and resequencing efforts to more precisely map causal genes...
  94. ncbi request reprint High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells
    Julia Blanco
    Retrovirology Laboratory, Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    J Biol Chem 279:51305-14. 2004
    ....
  95. doi request reprint Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5
    Mercedes Armand-Ugon
    Retrovirology Laboratory irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Spain
    J Antimicrob Chemother 65:417-24. 2010
    ..We have analysed the resistance profile of two R5 HIV-1 strains [BaL and a clinical isolate (CI)] after long-term passage in cell culture in the presence of TAK-779, the first developed non-peptidic small molecule targeting CCR5...
  96. doi request reprint A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study
    Bonaventura Clotet
    Hospital Universitari Germans Trias I Pujol and irsiCaixa Foundation, Ctra de Canyet s n, 08916 Barcelona, Spain
    J Antimicrob Chemother 62:1374-8. 2008
    ....
  97. doi request reprint Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Antimicrob Chemother 62:784-92. 2008
    ....
  98. ncbi request reprint Evaluation of the anti-HIV activity of statins
    Gemma Moncunill
    Retrovirology Laboratory IrsiCaixa and HIV Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Spain
    AIDS 19:1697-700. 2005
    ..No anti-HIV activity was detected at subtoxic concentrations and simvastatin did not induce a significant change in the mean viral load or CD4 cell count in study patients. We caution on the use of statins as antiretroviral agents...
  99. ncbi request reprint Strategies for overcoming resistance in HIV-1 infected patients receiving HAART
    Bonaventura Clotet
    HIV Clinical Unit, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    AIDS Rev 6:123-30. 2004
    ..g. atazanavir and tenofovir) have become available. These characteristics thus increase the likelihood of durable viral suppression...
  100. doi request reprint Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure
    Josep M Llibre
    Lluita contra la SIDA Foundation, Hospital Germans Trias, Universitat Autonoma of Barcelona, Barcelona, Spain
    Clin Infect Dis 50:872-81. 2010
    ..Determining the most active drugs and successfully combining them is the key challenge in salvage regimens...
  101. ncbi request reprint Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy
    Mariona Parera
    Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, and Universitat Autonoma de Barcelona, Barcelona, Spain
    J Infect Dis 189:1444-51. 2004
    ..Taken together, these results show a lack of clinically relevant evolution in the protease-coding region after 2 years of successful HAART...